Safety and Efficacy of Vonoprazan vs Proton Pump Inhibitor With Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection

Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that infects up to 50% of the world's population, residing in the gastric mucosa and using the mucus layer for protection from the stomach's high acidity. Its clinical significance is profound: it is classified as a Group 1 carcinogen by the World Health Organization and is a primary cause of chronic gastritis, peptic ulcers, gastric lymphoma, and gastric carcinoma. The current first-line treatment, a PPI-based triple therapy (PPI + clarithromycin + amoxicillin), is experiencing a decline in efficacy (cure rates of 50-70%) due to widespread antibiotic resistance and compliance issues. To overcome this, newer agents like Vonoprazan Fumarate, a Potassium-Competitive Acid Blocker (P-CAB), are being adopted. Vonoprazan works by reversibly inhibiting the H+, K+ ATPase pump achieving stronger and longer-lasting acid suppression than PPIs because it does not require acid activation and is more stable in an acidic environment. In addition to pharmacological treatment, adjunctive therapies show promise. Vitamin D, acting through Vitamin D Receptor (VDR), assists in eradication by upregulating antimicrobial proteins like beta-defensin and cathelicidin, and its metabolite can cause bacterial cell lysis. Probiotics (primarily Lactobacillus and Bifidobacterium strains) enhance eradication rates by restricting bacterial growth, inhibiting adhesion, and exerting an anti-inflammatory effect through decreased interleukin-8 production. Finally, helicobacter pylori infection is marked by significant inflammation and oxidative stress. The bacterial protein TIP alpha induces high levels of the pro-inflammatory cytokine TNF alpha. Furthermore, the infection increases free radical production, leading to oxidative stress reflected by high levels of malondialdehyde. Systemic inflammation is also evident as helicobacter pylori infection is associated with significantly elevated serum C-reactive protein levels, which decrease upon successful eradication.
Aim of the work:
This study aims at evaluating the safety and efficacy of Vonoprazan vs Proton Pump Inhibitor with Vitamin D or Probiotics Based Triple Therapy for Eradication of Helicobacter Pylori Infection.

开始日期2026-02-15

申办/合作机构

Tanta University

CTIS2024-520153-21-00

/ Active, not recruiting临床1期

An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Clarithromycin tablets 500 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Clarithromycin 500 mg coated tablets Manufactured by: Sanofi Medley Pharmaceuticals Ltd. Brazilian Industry, in healthy adult, human subjects under fasting condition.

开始日期2026-01-29

申办/合作机构

Sun Pharmaceutical Industries Ltd.

NCT07341100

/ Not yet recruiting临床2期

A Multicenter, Open-label Clinical Study to Evaluate the Preliminary Efficacy of SKB264 and the Effect of Clarithromycin, a Potent CYP3A Inhibitor, on the Pharmacokinetics of SKB264 in Patients With Ovarian Epithelial Cancer

This is a multicenter, open-label study to evaluate the preliminary efficacy of SKB264 and the effect of clarithromycin on the PK of SKB264 in patients with ovarian epithelial cancer.

开始日期2026-01-01

申办/合作机构

四川科伦博泰生物医药股份有限公司

100 项与克拉霉素相关的临床结果

登录后查看更多信息

100 项与克拉霉素相关的转化医学

登录后查看更多信息

100 项与克拉霉素相关的专利（医药）

登录后查看更多信息

13,626

项与克拉霉素相关的文献（医药）

2026-06-01·Archivos Argentinos de Pediatria

Brain abscess caused by Mycobacterium avium complexin an adolescent with an inborn error of immunity

Article

作者: Squassi, Isabel ; Garrigue, Carolina ; Santelli, Luciana ; Feuerstein, Manuel ; Gonçalves Neiva Novo, María C ; Manonelles, Gabriela ; Gómez Raccio, Andrea

Mycobacterium avium complex (MAC) infections of the central nervous system are rare and represent a diagnostic challenge, especially in immunocompromised patients. Comprehensive management requires early diagnosis, prolonged antimicrobial treatment, and, in some cases, neurosurgical interventions. We present the case of a 16-year-old patient with an inborn error of immunity caused by a variant in the NFKB1A gene, who consulted for paresis of the left upper limb. A diagnosis of brain abscess was made using central nervous system (CNS) imaging, and the etiological agent was confirmed by neurosurgical biopsy culture after an unfavorable clinical course with initial empirical treatment. The patient was treated with rifampicin, ethambutol, levofloxacin, linezolid, clarithromycin, and high-dose dexamethasone, achieving significant clinical and radiological improvement after prolonged treatment.

2026-05-01·TALANTA

Piezoelectric printing-based droplet digital PCR for noninvasive and sensitive detection of Helicobacter pylori in stool samples

Article

作者: Kong, Mengqi ; Hou, Zhennan ; Li, Siyu ; Liu, Zhaonan ; Zhang, Chuyao ; Li, Zedong ; Jin, Birui ; Li, Zonghao ; Hu, Jie

Helicobacter pylori (H. pylori), classified by the WHO as a Group I carcinogen, is a major contributor to progressive gastric diseases, and its growing resistance to antibiotics has severely undermined first-line eradication therapies. Conventional stool-based diagnostics face three key limitations: limited ability to detect resistant strains, labor-intensive culture workflows, and insufficient sensitivity in inhibitor-rich matrices. These shortcomings underscore the urgent need for a noninvasive, highly sensitive, and inhibitor-tolerant platform that enables simultaneous pathogen detection and resistance assessment. To address this unmet need, we developed a piezoelectric printing-driven ddPCR platform. By optimizing piezoelectric parameters and oil-phase surfactant formulations, we achieved uniform and stable droplet generation, producing a high-density microarray of ∼30,000 droplets in 3 min. The droplets exhibited excellent thermal stability, enabling robust digital PCR amplification. Using stool samples, the platform simultaneously detected H. pylori infection and clarithromycin resistance mutations. For H. pylori detection, it exhibited a sensitivity of 1 copy/μL, a quantitative linear range of 10⁰-10⁵ copies/μL (R² = 0.99), and 100 % concordance with commercial assays. This technology provides a scalable, cost-effective, and clinically practical solution for stool-based pathogen detection and antimicrobial resistance surveillance, advancing precision diagnostics in both clinical and public health settings.

2026-05-01·JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS

Analysis of gut microbiota and intestinal secondary bile acids metabolism in rats after short-term antibiotic treatment

Article

作者: Yang, Zhuan ; Yu, Yunli ; Lv, Bo ; Zhang, Xiaoping

Antibiotics have a profound impact on the overall taxonomic composition of gut microbiota. As gut microbiota influence host bile acids metabolism, changes in the composition of gut microbiota induced by antibiotics are certain to alter host bile acids profile. However, the differences in the effects of various antibiotics on bile acids metabolism and their associations with the impact on intestinal microbiota remain unelucidated. Here, investigation was conducted into how different antibiotics impact host intestinal bile acids metabolism via gut microbiota using in vivo study and multi-omics approaches. Four antibiotics (cefixime, clarithromycin, moxifloxacin and metronidazole) were used to treat normal rats for a short period (3 days), and then gut microbiota, intestinal bile acids profile, BSH and 7α-dehydroxylases activity mediated bile acid metabolism were measured. The results showed that bile acid metabolism in intestine was significantly altered along with the abundance change in bile acid-producing microbiota. It was found that moxifloxacin and metronidazole inhibited the transformation of primary BAs to secondary BAs in the intestine as compared to cefixime and clarithromycin, which was exposed to be associated with its regulation of Ruminococcaceae by Spearman's correlation analysis (correlation with CDCA/LCA is r = -0.89, FDR<0.001 and CA/DCA is r = -0.708, FDR<0.01). The abundance of Ruminococcaceae in the gut decreased by 87 % after moxifloxacin intervention, while metronidazole completely suppressed the abundance of intestinal Ruminococcaceae. Further analysis revealed that Ruminococcaceae were most strongly associated with the activity of 7α-dehydroxylases (r = 0.701, FDR<0.001). Specifically, we found that Ruminococcus flavefaciens had the closest association with alterations in secondary bile acids (r < -0.68, FDR<0.01). Collectively, our research demonstrated that different antibiotics exerted varying impacts on the production of intestinal secondary bile acids, which was related to their differential effects on the gut microbiota. This work provides novel insights into the interplay between antibiotics and microbial metabolites.

445

项与克拉霉素相关的新闻（医药）

2026-02-26

·北京医学感染与传染研究

柳叶刀传染病学 26卷 1-3期（2026年2月26日更新）

THE LANCET Infectious Diseases. Volume 26Number 1 柳叶刀传染病学 26卷 1期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Urgent need for infection prevention and control in prisons 监狱中感染预防和控制的迫切需求 The Lancet Infectious Diseases The Lancet Infectious Diseases Vol 26(1):p1 COMMENT（述评） 2 Now is the time to integrate serology into routine infectious disease surveillance 现在是时候将血清学纳入常规传染病监测了 Simon Cauchemez The Lancet Infectious Diseases Vol 26(1):p2 3 Reassessing sotrovimab's role in COVID-19: insights and implications 重新评估索托维单抗在新冠肺炎治疗中的作用：见解与启示 Daniele Focosi,Fabrizio Maggi The Lancet Infectious Diseases Vol 26(1):p3 4 Shaping opportunities for future clinical trials in tuberculosis 为未来结核病临床试验创造机会 Ivan Noreña,Beno Mbeya,Joanitah Nalunjogi,Ombeni Chimbe,Norbert Heinrich The Lancet Infectious Diseases Vol 26(1):p5 5 Diversifying antimalarial treatment for uncomplicated Plasmodium falciparum malaria in Uganda 乌干达针对无并发症恶性疟原虫疟疾的抗疟治疗多样化 Arjen M Dondorp The Lancet Infectious Diseases Vol 26(1):p6 6 A safe start for PfSPZ Vaccine, but efficacy in children remains elusive PfSPZ疫苗安全起步，但在儿童中的疗效仍难以捉摸 Nicholas Aderinto,Temitomi Jane Oyedele The Lancet Infectious Diseases Vol 26(1):p8 7 Rifasutenizol-based triple therapy for Helicobacter pylori infection 以利法苏替尼唑为基础的三联疗法治疗幽门螺杆菌感染 Jinnan Chen,Hong Lu The Lancet Infectious Diseases Vol 26(1):p9 8 The smallest faith 最渺小的信念 Steven A Pergam The Lancet Infectious Diseases Vol 26(1):p11 9 Negative results in long COVID clinical trials: choosing outcome measures for a heterogeneous disease 新冠肺炎长期症状临床试验的阴性结果：为异质性疾病选择预后指标 Lara Goxhaj,Lisa McCorkell,Femke van Rhijn-Brouwer,Letícia Soares,Julia Moore Vogel,Chloé de Canson The Lancet Infectious Diseases Vol 26(1):p13 10 Strengthening global preparedness and response to arboviral disease threats: a call to action 加强全球应对虫媒病毒疾病威胁的准备和响应：行动呼吁 WHO Global Arbovirus Initiative Technical Advisory Group 世界卫生组织全球虫媒病毒倡议技术咨询小组 The Lancet Infectious Diseases Vol 26(1):p15 11 Introducing our cover artist for 2026: Daria Lada 介绍我们2026年的封面艺术家：达里亚·拉达 Marco De Ambrogi The Lancet Infectious Diseases Vol 26(1):p17 Correspondence（读者来信） 12 Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2 新兴新冠病毒变异株BA.3.2的流行病学和病毒学最新情况 Lu Zhang,Nianzhen Chen,Amy Eichmann,Inga Nehlmeier,Anna-Sophie Moldenhauer,Metodi V Stankov,Christine Happle,Alexandra Dopfer-Jablonka,Georg M N Behrens,Markus Hoffmann,Stefan Pöhlmann The Lancet Infectious Diseases Vol 26(1):e1 13 Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation Christine Happle,Markus Hoffmann,Metodi V Stankov,Inga Nehlmeier,Amy Eichmann,Torsten LP.8.1适应性mRNA疫苗接种对新冠病毒变异株中和作用的影响 Witte,Luis Manthey,Stefan Pöhlmann,Alexandra Dopfer-Jablonka,Georg M N Behrens The Lancet Infectious Diseases Vol 26(1):e3 14 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致 Nader Ebrahimi,Amir Ghaemi The Lancet Infectious Diseases Vol 26(1):e6 15 Artificial intelligence and spillover prediction: aligning innovation with empirical reality in One Health surveillance – Authors' reply 人工智能与溢出预测：在“同一健康”监测中使创新与经验现实保持一致——作者回复 Frank Aarestrup,Marion Koopmans The Lancet Infectious Diseases Vol 26(1):e7 16 Time to tackle vaccine–HLA associations with artificial intelligence 是时候用人工智能解决疫苗-人类白细胞抗原关联问题了 Alexander J Mentzer,George Davey Smith,Teresa Lambe,Julian C Knight,Mary Carrington The Lancet Infectious Diseases Vol 26(1):e8 Corrections（更正） 17 Correction to Lancet Infect Dis 2025; published online Oct 29. 《柳叶刀-传染病》2025年更正；在线发表于10月29日 https://doi.org/10.1016/S1473-3099(25)00466-9 The Lancet Infectious Diseases Vol 26(1):e9 18 Correction to Lancet Infect Dis 2025; published online Oct 27. 《柳叶刀-传染病》2025年更正；在线发表于10月27日 https://doi.org/10.1016/S1473-3099(25)00546-8 The Lancet Infectious Diseases Vol 26(1):e9 19 Correction to Lancet Infect Dis 2025; 25: 1084–96 《柳叶刀-传染病》2025年更正；25卷：1084-1096页 The Lancet Infectious Diseases Vol 26(1):e9 20 Correction to Lancet Infect Dis 2025; published online Nov 10. 《柳叶刀-传染病》2025年更正；在线发表于11月10日 https://doi.org/10.1016/S1473-3099(25)00550-X The Lancet Infectious Diseases Vol 26(1):e9 Newsdesk（新闻台） 21 Highlights of IDWeek 2025 2025年IDWeek亮点 Phoebe Hall The Lancet Infectious Diseases Vol 26(1):e10 22 WHO publishes update on global antibiotic resistance 世界卫生组织发布全球抗生素耐药性最新情况 Timothy Jesudason The Lancet Infectious Diseases Vol 26(1):e11 23 European Commission to fund new medicines for dengue 欧盟委员会资助登革热新药研发 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):e12 24 Second report from the UK Covid-19 Inquiry 英国新冠肺炎调查第二次报告 Talha Burki The Lancet Infectious Diseases Vol 26(1):e13 25 Infectious disease surveillance update 传染病监测最新情况 Cahal McQuillan The Lancet Infectious Diseases Vol 26(1):e14 26 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases Vol 26(1):e15 Obituary（讣告） 27 Jean Louis Abdourahim Ndiaye 让·路易斯·阿卜杜拉希姆·恩迪亚耶 Sanjeet Bagcchi The Lancet Infectious Diseases Vol 26(1):p19 Profile（人物介绍） 28 Fortunate Machingura—tackling climate change and disease 福图纳特·马辛古拉——应对气候变化与疾病 Tony Kirby The Lancet Infectious Diseases Vol 26(1):p20 Media Watch（媒体观察） Book（书籍） 29 The social and political drivers behind pandemics 大流行背后的社会和政治驱动因素 Emma Louise Fabiani The Lancet Infectious Diseases Vol 26(1):p21 Articles（论著） 30 Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022–23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study 新冠肺炎疫情后美国儿童地方性病毒重新出现的动态（2022-23年）：一项前瞻性、多中心、纵向、免疫流行病学监测研究 Hai Nguyen-Tran,Sang Woo Park,Matthew R Vogt,Perdita Permaul,Alicen B Spaulding,Michelle L Hernandez,Jennifer A Bohl,Sucheta Godbole,Tracy J Ruckwardt,Peter W Krug,Daniel L Moss,Alexandrine Derrien-Colemyn,Ananda Chowdhury,Gabrielle Dziubla,Lu Wang,Mike Castro,Sandeep R Narpala,Elizabeth R Longtine,Amy R Henry,Teri-T B Ngo,Leonid Dzantiev,George B Sigal,C Jessica Metcalf,David W Kimberlin,Samuel R Dominguez,Abraham Mittelman,Adrian B McDermott,Leonid A Serebryannyy,Bryan Grenfell,Kevin Messacar,Daniel C Douek The Lancet Infectious Diseases Vol 26(1):p22 31 Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial 索托维单抗与常规治疗对住院新冠肺炎患者的疗效对比（RECOVERY）：一项随机、对照、开放标签、平台试验 RECOVERY Collaborative Group RECOVERY协作组 The Lancet Infectious Diseases Vol 26(1):p34 32 A 3-month clofazimine–rifapentine-containing regimen for drug-susceptible tuberculosis versus standard of care (Clo-Fast): a randomised, open-label, phase 2c clinical trial 含氯法齐明-利福喷丁的3个月方案与标准治疗方案治疗药物敏感性结核病的对比（Clo-Fast）：一项随机、开放标签、2c期临床试验 John Z Metcalfe,Isabelle R Weir,Kimberly K Scarsi,Alberto Mendoza-Ticona,Samuel Pierre,Luke Hall,Jorge Leon-Cruz,Elin M Svensson,Simon E Koele,Wadzanai Samaneka,Cecilia Kanyama,Maxwell Yohane,Neetal Nevrekar,Busisiwe Ntsalaze,Jean Bernard Marc,Melanie Goth,Gary Maartens,Richard Chaissonon behalf of the ACTG A5362 study team The Lancet Infectious Diseases Vol 26(1):p46 33 Global policy responses to antimicrobial resistance, 2021–22: a systematic governance analysis of 161 countries and territories 2021-22年全球应对抗菌药物耐药性的政策反应：对161个国家和地区进行的系统性治理分析 Jay Patel,Sahar Saeedi Moghaddam,Sruthi Ranganathan,Neil Vezeau,Emily O'Neill,Anne Harant,Michael Stolpe,Lothar H Wieler,Tim Eckmanns,Devi Sridhar The Lancet Infectious Diseases Vol 26(1):p55 34 Efficacies of artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperaquine, and artesunate–pyronaridine for the treatment of uncomplicated Plasmodium falciparum malaria in children aged 6 months to 10 years in Uganda: a randomised, open-label, phase 4 clinical trial 乌干达6个月至10岁儿童使用蒿甲醚-本芴醇、青蒿琥酯-阿莫地喹、双氢青蒿素-哌喹和青蒿琥酯-吡喃隆治疗无并发症恶性疟原虫疟疾的疗效：一项随机、开放标签、4期临床试验 Moses R Kamya,Joaniter I Nankabirwa,Chris Ebong,Victor Asua,Moses Kiggundu,Stephen Orena,Martin Okitwi,Stephen Tukwasibwe,Bosco Agaba,Daniel Kyabayinze,Jimmy Opigo,Damian Rutazana,Benjamin Binagwa,Edward Mugwanya,Shakira Babirye,Gloria Sebikaari,Patrick M Condo,Grace Appiah,Sam L Nsobya,Melissa D Conrad,Philip J Rosenthal,Leah F Moriarty,Adoke Yeka The Lancet Infectious Diseases Vol 26(1):p67 35 Safety, tolerability, and protective efficacy of a radiation-attenuated, whole sporozoite malaria vaccine in children in Gabon: a randomised, double-blind, placebo-controlled, phase 2 trial 加蓬儿童使用辐射减毒全孢子虫疟疾疫苗的安全性、耐受性和保护效力：一项随机、双盲、安慰剂对照、2期试验 Selidji T Agnandji,Jeroen Bok,Ayodele Alabi,Anita L Kabwende,Armel Mbouna,Juste Bie,Eleonne Moukiti,Albert Lalremruata,Meral Esen,Andrea Kreidenweiss,Natasha KC,B Kim Lee Sim,Thomas L Richie,L W Preston Church,Matthew B B McCall,Stephen L Hoffman,Peter G Kremsner,Benjamin Mordmüller The Lancet Infectious Diseases Vol 26(1):p79 36 Effectiveness of the TAK-003 dengue vaccine in adolescents during the 2024 outbreak in São Paulo, Brazil: a test-negative, case–control study TAK-003登革热疫苗在2024年圣保罗暴发期间对青少年的有效性：一项测试阴性病例对照研究 Otavio T Ranzani,Felippe Lazar Neto,Lisany Krug Mareto,Thiago Sanches Brumatti,Roberto Dias de Oliveira,Patricia Vieira da Silva,Edinéia Ribeiro dos Santos,Tatiana Lang D' Agostini,Regiane A Cardoso De Paula,Natalie E Dean,Albert I Ko,Derek A T Cummings,Jason R Andrews,Matt D T Hitchings,Julio Croda The Lancet Infectious Diseases Vol 26(1):p91 37 Rifasutenizol-based triple therapy versus bismuth plus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection in China (EVEREST-HP): a phase 3, multicentre, randomised, triple-dummy, double-blind, controlled, non-inferiority trial 以利法苏替尼唑为基础的三联疗法与铋剂加克拉霉素为基础的三联疗法作为中国幽门螺杆菌感染一线治疗的对比（EVEREST-HP）：一项3期、多中心、随机、三模拟、双盲、对照、非劣效性试验 Zhiqiang Song,Liya Zhou,Weihong Wang,Cheng Lan,Tongyu Tang,Jun Xie,Huizhen Fan,Xuehong Wang,Xiuli Zuo,Yin Zhu,Chengxia Liu,Yongsong Gu,Huang Feng,Xiang Gao,Qing Zhang,Hong Zhang,Jing Chen,Guozhu Geng,Zhenkun Maon behalf of the EVEREST-HP Study Group The Lancet Infectious Diseases Vol 26(1):p101 Series（专题研讨会） 38 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Innovation in active and passive immunisation of people who are immunocompromised: a call to action 免疫功能低下人群主动和被动免疫接种的创新：行动呼吁 Joshua A Hill,Jim Boonyaratanakornkit,Malgorzata Mikulska,Benjamin W Teh,William O Hahn,Ghady Haidar,Catherine Liu,Deepali Kumar,Michael G Ison,Natasha Halasa The Lancet Infectious Diseases Vol 26(1):e16 39 Prevention and Management of Infections in People who are Immunocompromised 免疫功能低下人群感染的预防和治疗 Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship 应对免疫功能低下人群的抗菌药物耐药性：利用诊断和抗菌药物管理 Catherine Liu,Emily A Rosen,Erica J Stohs,Hannah Imlay,Masayuki Nigo,Lee S Gottesdiener,Miranda So,Frank Tverdek,Sanjeet Dadwal,Carlota Gudiol,Michael J Satlin,Susan K Seo,Jason A Trubiano,Ritu Banerjee,Kimberly E Hanson,Lilian M Abbo The Lancet Infectious Diseases Vol 26(1):e30 Review（综述） 40 Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project 揭示欧洲肺泡棘球蚴病的发病率和趋势：来自KNOW-PATH项目的系统综述 Adriano Casulli,Bernadette Abela,Daniele Petrone,Barbara Šoba,Balázs Dezsényi,Jacek Karamon,Laurence Millon,Urmas Saarma,Daniela Antolová,François Chappuis,Severin Gloor,Marcel Stoeckle,Beat Müllhaupt,Relja Beck,Heimo Lagler,Felix Lötsch,Herbert Auer,Marie-Pierre Hayette,Libuše Kolářová,Sniedze Laivacuma,Mindaugas Šarkūnas,Vitalijus Sokolovas,Audronė Marcinkutė,Karin Troell,Ansgar Deibel,Pikka Jokelainen,Małgorzata Sulima,Dagny Krankowska,Stillhard Roman,Gaëtan-Romain Joliat,Nermin Halkic,Solange Bresson-Hadni,Joanna Halina Bednarek,Andrzej Załęski,Małgorzata Paul,Sheraz Yaqub,Mogens Jensenius,Joke van der Giessen,Laura Nabarro,Peter Chiodini,Florent Demonmerot,Jenny Knapp,Beate Grüner,Peter Kern,Lynn Peters,Federica Santolamazza,Azzurra Santoro The Lancet Infectious Diseases Vol 26(1):e49 Personal View（个人观点） 41 Azithromycin mass drug administration: balancing survival benefits and risks in children 阿奇霉素大规模药物给药：平衡儿童生存益处与风险 Nubwa Medugu,Ian C Michelow,Claudette Poole,Stephen K Obaro The Lancet Infectious Diseases Vol 26(1):e62 Clinical Picture（临床影像） 42 Unexpected finding in a 17-year-old female undergoing screening colonoscopy 17岁女性接受筛查结肠镜检查时的意外发现 Ziheng Calvin Xu,Ethan Tan,Mayur Garg The Lancet Infectious Diseases Vol 26(1):e75 THE LANCET Infectious Diseases. Volume 26Number 2 柳叶刀传染病学 26卷 2期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL(社论) 1 Call for letters 征稿启事 The Lancet Infectious Diseases The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p111 Comment（述评） 2 Long COVID is here to stay—even in children 长期新冠症状将持续存在——即使在儿童中亦是如此 Danilo Buonsenso The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p112 3 Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment 利托那韦强化版奈玛特韦之外的选择：恩赛特韦在新冠肺炎治疗中的应用 Ming Hong Choi,Ivan Fan Ngai Hung The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p113 4 A new monoclonal in the arMAMentarium against malaria 抗疟“武器库”中的新型单克隆抗体 Freia-Raphaella Lorenz,Matthew B B McCall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p115 5 Household transmission of mpox in Africa: limited in adults but more prevalent in children 非洲猴痘家庭传播情况：在成人中传播有限，但在儿童中更为普遍 Oriol Mitjà,Michael Marks The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p117 6 The lasting lessons of mpox: infection, vaccination, and immune memory 猴痘带来的持久教训：感染、疫苗接种和免疫记忆 Raianna Fantin,Camila H Coelho The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p118 7 Xpert-Ultra for diagnosing asymptomatic tuberculosis Xpert-Ultra用于诊断无症状结核病 Xia Yu,Hairong Huang The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p120 8 The genomic surveillance gap: averting the antimicrobial resistance pandemic requires global equity and action 基因组监测的差距：避免抗菌药物耐药性大流行需要全球公平与行动 David M Aanensen,Iruka N Okeke,Pilar Donado-Godoy,Beverly Egyir,Ravikumar K Lingegowda,Sonia Siaon behalf of the NIHR Global Health Research Unit on Genomic Surveillance of AMR The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p122 Correspondence（读者来信） 9 Spillover in dengue trials 登革热试验中的溢出效应 Thomas A Smith,Samuel I Watson The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e77 10 Spillover in dengue trials – Author's reply 登革热试验中的溢出效应——作者回复 Fernando Abad-Franch The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e78 11 Updating the traditional voriconazole trough concentration range 传统的伏立康唑谷浓度范围更新 Rongqiang Liao,Xiaoyuan Zheng The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e79 12 Updating the traditional voriconazole trough concentration range – Authors' reply 传统的伏立康唑谷浓度范围更新——作者回复 Inderpaul Singh Sehgal,Ritesh Agarwal,Valliappan Muthu The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e80 13 Clinical course and neurological profile of Kyasanur Forest disease 基萨努尔森林病的临床病程和神经特征 Nitin Gupta,Tirlangi Praveen Kumar The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e82 Corrections（更正） 14 Correction to Lancet Infect Dis 2025; published online Oct 10. https://doi.org/10.1016/S1473-3099(25)00482-7 对《柳叶刀-传染病》2025年发表内容的更正；10月10日在线发表。https://doi.org/10.1016/S1473-3099(25)00482-7 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 15 Correction to Lancet Infect Dis 2025; published online Dec 1. https://doi.org/10.1016/S1473-3099(25)00681-4 对《柳叶刀-传染病》2025年发表内容的更正；12月1日在线发表。https://doi.org/10.1016/S1473-3099(25)00681-4 The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e83 Newsdesk（新闻台） 16 Promising early data for sorfequiline 索氟维林早期数据令人鼓舞 Ed Holt The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e84 17 Highlights from ASTMH 2025 2025年美国热带医学与卫生学会年会亮点 Marco De Ambrogi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e85 18 Brazil approves domestic single-shot dengue vaccine 巴西批准国产单剂登革热疫苗 Marcia Triunfol The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e86 19 CDC cuts to childhood vaccine recommendations 美国疾控中心削减儿童疫苗接种建议 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e87 20 WHO launches unified plan for coronaviruses 世界卫生组织启动冠状病毒统一计划 Talha Burki The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e88 21 Infectious disease surveillance update 传染病监测更新 Cahal McQuillan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e89 22 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e90 Obituary（讣告） 23 Walter Dowdle 沃尔特·道德尔 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p124 Profile（人物简介） 24 Katie Anders—improving global dengue control 凯蒂·安德斯——改善全球登革热防控 Tony Kirby The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p125 Media Watch（媒体观察） Film（电影） 25 Eliminating Guinea worm 根除麦地那龙线虫 Sanjeet Bagcchi The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p126 Articles（论著） 26 Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study 奥密克戎时代儿童与青少年长期新冠症状与SARS-CoV-2再感染的关联（RECOVER-EHR）：一项回顾性队列研究 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Ting Zhou,Michael J Becich,Yuriy Bisyuk,Frank Blanceró,Elizabeth A Chrischilles,Cynthia H Chuang,Lindsay G Cowell,Daniel Fort,Carol R Horowitz,Susan Kim,Nathalia Ladino,David M Liebovitz,Mei Liu,Abu S M Mosa,Hayden T Schwenk,Srinivasan Suresh,Bradley W Taylor,David A Williams,Jeffrey S Morris,Christopher B Forrest,Yong Chenon behalf of the RECOVER Consortium The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p127 27 Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial 口服恩赛特韦与口服利托那韦强化版奈玛特韦在新冠肺炎治疗中的抗病毒疗效（PLATCOV）：一项开放标签、2期、随机、对照、适应性试验 William H K Schilling,Podjanee Jittamala,Phrutsamon Wongnak,James A Watson,Simon Boyd,Viravarn Luvira,Tanaya Siripoon,Thundon Ngamprasertchai,Elizabeth M Batty,Ellen Beer,Shivani Singh,Tanatchakorn Asawasriworanan,Timothy Seers,Koukeo Phommasone,Terry John Evans,Varaporn Kruabkontho,Thatsanun Ngernseng,Jaruwan Tubprasert,Mohammad Yazid Abdad,Wanassanan Madmanee,Jindarat Kouhathong,Kanokon Suwannasin,Watcharee Pagornrat,Tianrat Piteekan,Borimas Hanboonkunupakarn,Kittiyod Poovorawan,Manus Potaporn,Attasit Srisubat,Bootsakorn Loharjun,Kesinee Chotivanich,Mallika Imwong,Sasithon Pukrittayakamee,Arjen M Dondorp,Nicholas P J Day,Watcharapong Piyaphanee,Weerapong Phumratanaprapin,Nicholas J Whiteon behalf of the PLATCOV Collaborative Group The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p139 28 Cefiderocol versus standard therapy for hospital-acquired and health-care-associated Gram-negative bacterial bloodstream infection (the GAME CHANGER trial): an open-label, parallel-group, randomised trial 头孢地尔与标准疗法治疗医院获得性和医疗保健相关性革兰氏阴性菌血流感染（GAME CHANGER试验）：一项开放标签、平行分组、随机试验 David L Paterson,Helmi Sulaiman,Po-Yu Liu,Mark D Chatfield,Mesut Yilmaz,Zeti Norfidiyati Salmuna,Mohd Zulfakar Mazlan,Siriluck Anunnatsiri,Rujipas Sirijatuphat,Darunee Chotiprasitsakul,David C Lye,Jyoti Somani,Shirin Kalimuddin,Abdullah T Aslan,Visanu Thamlikitkul,Yi-Tzu Lee,Ya-Sung Yang,Yi-Tsung Lin,Wan Nurliyana Wan Ramli,Chien-Hao Tseng,Sophia Archuleta,Yvonne Fu Zi Chan,Brian M Forde,Hugh Wright,Adam G Stewart,Kay A Ramsay,Weiping Ling,Vicki Rossi,Tiffany M Harris-Brown,Patrick N A Harrison behalf of the GAME CHANGER Trial Investigators The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p148 29 Efficacy and safety of ascending doses of orodispersible ivermectin co-administered with albendazole for Trichuris trichiura infections in preschool-aged children in Tanzania: a 坦桑尼亚学龄前儿童感染毛首鞭形线虫时，递增剂量口服分散片伊维菌素与阿苯达唑联合用药的疗效和安全性：一项单盲、随机、对照、剂量递增、2期试验 single-blind, randomised, controlled, dose-ranging, phase 2 trial Viviane P Sprecher,Annina Schnoz,Stefan Biendl,Halima S Hussein,Sarah O Najim,Mohammed N Ali,Ibrahim S Mohammed,Said M Ali,Jan Hattendorf,Jennifer Keiser The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p160 30 Human monoclonal antibody MAM01 for protection against malaria in adults in the USA: a first-in-human, phase 1, dose-escalation, double-blind, placebo-controlled, adaptive trial 人源单克隆抗体MAM01保护美国成年人免受疟疾侵害：一项首次人体、1期、剂量递增、双盲、安慰剂对照、适应性试验 Kirsten E Lyke,Andrea A Berry,Matthew B Laurens,Jennifer Winkler,Sudhaunshu Joshi,Abra Rachida Koudjra,Lauryn Butler,Peter F Billingsley,Tales Pascini,Asha Patil,B Kim Lee Sim,Grace Fitzgerald,Julie Riegel,Kayla Andrews,Micha Levi,Aparna B Anderson,Charles D Wells,Hong Liu,James Huleatt,R Scott Miller The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p170 31 Characterising household transmission dynamics of clade Ib mpox in Burundi: a prospective cohort study 布隆迪Ib分支猴痘家庭传播动力学特征：一项前瞻性队列研究 Raoul Kamadjeu,Ferdinand Nsengimana,Manassé Nimpagaritse,Edna Moturi,Eric Kezakarayagwa,Rose Nkiko,Jonas Ngendakumana,Rémy Nimubona,Liliane Nkengurutse,Hamady Ba,Dionis Nizigiyimana,Paul Ngwakum,Mame Selbee Diouf,France Bégin,Joseph Nyandwi,Douglas James Noble The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p182 32 Long-term consequences of monkeypox virus infection or modified vaccinia virus Ankara vaccination in Belgium (MPX-COHORT and POQS-FU-PLUS): a 24-month prospective and retrospective cohort study 比利时猴痘病毒感染或改良痘苗病毒安卡拉株疫苗接种的长期后果（MPX-COHORT和POQS-FU-PLUS）：一项为期24个月的前瞻性和回顾性队列研究 Christophe Van Dijck,Nicole Berens-Riha,Luca M Zaeck,Cécile Kremer,Jacob Verschueren,Jasmine Coppens,Fien Vanroye,Elisabeth Willems,Evi Bosman,Natalie De Cock,Bart Smekens,Leen Vandenhove,Odin Goovaerts,Anke Van Hul,Janne Wouters,Bart K M Jacobs,Stefanie Bracke,Matilde Hens,Isabel Brosius,Elise De Vos,Eugene Bangwen,Sarah Houben,Achilleas Tsoumanis,Pedro Henrique Lopes Ferreira Dantas,Jojanneke Rutgers,Amber Lipman,Koen Wijnans,Patrick Soentjens,Emmanuel Bottieau,Chris Kenyon,Johan van Griensven,Thijs Reyniers,Niels Horst,Kevin K Ariën,Marjan Van Esbroeck,Andrea Torneri,Koen Vercauteren,Wim Adriaensen,Rory D de Vries,Joachim Mariën,Laurens Liesenborghs The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p190 33 Long-term risk of tuberculosis among individuals with Xpert Ultra trace screening results in Uganda: a longitudinal follow-up study 乌干达Xpert Ultra微量筛查结果阳性个体患结核病的长期风险：一项纵向随访研究 Joowhan Sung,Mariam Nantale,Annet Nalutaaya,Patrick Biché,James Mukiibi,Joab Akampurira,Rogers Kiyonga,Francis Kayondo,Michael Mukiibi,Caitlin Visek,Caleb E Kamoga,David W Dowdy,Achilles Katamba,Emily A Kendall The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：p203 Review（综述） 34 Invasive group A streptococcal infections: lessons learned from the 2022–23 upsurge 侵袭性A组链球菌感染：从2022-23年激增中吸取的教训 Alix Flamant,Alicia Demirjian,Theresa Lamagni,Julie Toubiana,Pierre R Smeesters,Jérémie F Cohen The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e91 35 A clinical practice guideline for tuberculous meningitis 结核性脑膜炎临床实践指南 Joseph Donovan,Fiona V Cresswell,Elizabeth W Tucker,Angharad G Davis,Ursula K Rohlwink,Julie Huynh,Regan Solomons,James A Seddon,Nathan C Bahr,Arjan van Laarhoven,Suzanne T Anderson,Sanjay K Jain,Felicia C Chow,Sophie Pattison,James E Scriven,Gabriela Singh,Rob E Aarnoutse,Jan-Willem C Alffenaar,Sofiati Dian,Abi Manesh,Robin Basu Roy,Varinder Singh,Ronald van Toorn,Caryn M Upton,Reinout van Crevel,Kelly E Dooley,Diana Gibb,David Meya,Robert J Wilkinson,Ewelina Rogozińska,Usha K Misra,Anthony Figaji,Guy E Thwaites The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e96 36 Towards shorter therapy for candidaemia: defining uncomplicated candidaemia in adults 缩短念珠菌血症疗程：界定成人非复杂性念珠菌血症 Ilana Reinhold,Susanne Picardi,Blasius Liss,Danila Seidel,Jannik Stemler,Philipp Koehler,Tamara Ruegamer,Rosanne Sprute,Oliver A Cornely The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e112 Personal View（个人观点） 37 A transformation in cholera surveillance 霍乱监测的变革 Amanda K Debes,Erin T Baumgartner,Kendra N Williams,David A Sack The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e124 Clinical Picture（临床图像） 38 Paediatric ocular toxocariasis with relentless progression despite negative metagenomic testing 尽管宏基因组检测呈阴性，但儿科眼弓蛔虫病仍持续进展 Diya Shah,Shiama Balendra,Harry Petrushkin,Anamika Patel The Lancet Infectious Diseases. Feb 2026，Vol 26(2)：e130 THE LANCET Infectious Diseases. Volume 26Number 3 柳叶刀传染病学 26卷 3期 https://www.thelancet.com/journals/laninf/issue/current EDITORIAL（社论） 1 Promises and challenges of AI in infectious diseases 人工智能在传染病领域的承诺与挑战 The Lancet Infectious Diseases The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p213 COMMENT（述评） 2 More real-world evidence for RSV vaccines in the global community 全球范围社区呼吸道合胞病毒（RSV）疫苗的更广泛的现实证据 Kristina L Bajema,Wesley H Self The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p214 3 Rapid diagnostic antigen tests for mpox and the need for decentralised testing—not quite there yet 猴痘快速诊断抗原检测及分散检测的必要性——尚待完善 Daniel Mukadi-Bamuleka,Kevin K Ariën The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p215 4 Solving the data bottleneck for artificial intelligence in infectious diseases 解决传染病人工智能领域的数据瓶颈问题 Cesar de la Fuente-Nunez The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p217 5 Artificial intelligence and One Health: potential for spillover prediction? 人工智能与“同一健康”理念：能否预测病原体外溢？ Marion Koopmans,Istvan Csabai,Daniel Remondini,Emma Snary,Frank Aarestrup The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p219 6 Artificial intelligence in the development of vaccines for infectious diseases 人工智能在传染病疫苗研发中的应用 Steve Black,Shabir A Madhi,Rino Rappuoli The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p221 7 Peer review at The Lancet Infectious Diseases in 2025 2025年《柳叶刀-传染病学》期刊专家评审 Ursula Hofer The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p223 8 Thank you to The Lancet Infectious Diseases statistical and peer reviewers in 2025 感谢2025年《柳叶刀-传染病学》期刊的统计学及评审专家 The Lancet Infectious Diseases Editors The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e132 CORRESPONDENCE（读者来信） 9 Methodological considerations in the attribution of long COVID to first or second infection 首次或二次感染导致长期新冠症状的方法学考量 Sara Carazo,Danuta M Skowronski,Manale Ouakki,Gaston De Serres The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e139 10 Methodological considerations in the attribution of long COVID to first or second infection – Authors' reply 首次或二次感染导致长期新冠症状的方法学考量——作者回复 Bingyu Zhang,Qiong Wu,Ravi Jhaveri,Christopher B Forrest,Yong Chen The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e141 11 Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2 LP.8.1单价疫苗针对包括XEC、LP.8.1、NB.1.8.1、XFG和BA.3.2在内的多种SARS-CoV-2变异株的体液免疫应答 Yu Kaku,Mizuka Fujiwara,Keiya Uriu,Maximilian Stanley Yo,Shusuke Kawakubo,Jumpei Ito,Naoya Itoh,Yoshifumi Uwamino,Fumitake Saito,Hironori Satoh,The Genotype to Phenotype Japan (G2P-Japan) Consortium,Kei Sato The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e142 12 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者 Brenda A Warecki,María F Mojica,Alejandro J Vila,Robert A Bonomo The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e144 13 Precision diagnostics for MBLs: the true game changer in treating antimicrobial resistance – Authors' reply 金属β-内酰胺酶精准诊断：治疗抗菌药物耐药性的真正变革者——作者回复 David L Paterson,Abdullah T Aslan,Patrick N A Harris The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e145 CORRECTIONS（更正） 14 Correction to Lancet Infect Dis 2025; published online Dec 9. https://doi.org/10.1016/S1473-3099(25)00659-0 《柳叶刀-传染病学》2025年发表文章勘误；在线发表于12月9日。https://doi.org/10.1016/S1473-3099(25)00659-0 The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 15 Correction to Lancet Infectious Diseases 2026; published online Jan 20. https://doi.org/10.1016/S1473-3099(25)00773-X 《柳叶刀-传染病学》2026年发表文章勘误；在线发表于1月20日。https://doi.org/10.1016/S1473-3099(25)00773-X The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e146 NEWSDESK（新闻台） 16 Rabies an increasing threat in Ukraine 乌克兰狂犬病威胁日益加剧 Ed Holt The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e147 17 People needing trachoma interventions at record low 需要沙眼干预措施的人数创历史新低 Timothy Jesudason The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e148 18 Uneven STI response in EU/EEA countries 欧盟/欧洲经济区国家性传播感染应对措施不均衡 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e149 19 Controversial HBV vaccine trial in Guinea-Bissau halted 几内亚比绍有争议的乙型肝炎病毒疫苗试验被叫停 Talha Burki The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e150 20 Research in brief 研究简讯 Priya Venkatesan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e151 OBITUARY（讣告） 21 Ivan Hirsch 伊万·赫希 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p224 PROFILE（人物介绍） 22 Reem Abu Shomar— championing water safety in Gaza 里姆·阿布·舒马尔——加沙地带水安全倡导者 Tony Kirby The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p225 MEDIA WATCH（媒体观察） Book（书籍） 23 A prescription for public health literacy 提升公众健康素养的良方 Vijay Shankar Balakrishnan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p226 Book（书籍） 24 Imagining the inevitable 想象不可避免之事 Cahal McQuillan The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p227 Film（电影） 25 Women's autonomy, safe sex and HIV prevention 女性自主权、安全性行为与艾滋病预防 Sanjeet Bagcchi The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p228 ARTICLES（论著） 26 Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75–79 years in England: a multicentre, test-negative, case–control study 英国75-79岁成年人中双价呼吸道合胞病毒（RSV）预融合F蛋白疫苗对RSV相关住院的有效性：一项多中心、检测阴性、病例对照研究 Rebecca Symes,Heather J Whitaker,Shazaad Ahmad,David Arnold,Suryabrata Banerjee,Cariad M Evans,Robin Gore,Jennifer Hart,Katy Heaney,Onn Min Kon,Anne Melhuish,Munira Ortale Zogaib,Emanuela Pelosi,Najib M Rahman,Gerrit Woltmann,Tricia McKeever,Maria Zambon,Conall H Watson,Wei Shen Lim,Jamie Lopez Bernalon behalf of the HARISS network collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p229 27 Oral itraconazole versus oral voriconazole for treatment-naive patients with chronic pulmonary aspergillosis in India (VICTOR-CPA trial): a single-centre, open-label, randomised, controlled, superiority trial 印度治疗初治慢性肺曲霉病患者口服伊曲康唑与口服伏立康唑的对比研究（VICTOR-CPA试验）：一项单中心、开放标签、随机、对照、优效性试验 Inderpaul Singh Sehgal,Ritesh Agarwal,Sahajal Dhooria,Kuruswamy Thurai Prasad,Valliappan Muthu,Ashutosh Nath Aggarwal,Shivaprakash M Rudramurthy,Mandeep Garg,Arunaloke Chakrabarti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p239 28 Accounting for non-adherence to assigned antibiotic treatment duration for bloodstream infection (BALANCE): a post-hoc analysis of a randomised clinical trial 血流感染抗生素治疗疗程依从性考量（BALANCE）：一项随机临床试验的事后分析 Sean W X Ong,Ruxandra Pinto,Robert K Mahar,Asgar Rishu,Joshua S Davis,Robert A Fowler,Steven Y C Tong,Nick Danemanfor the BALANCE trial consortium The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p250 29 Field evaluation of a rapid antigen test for mpox in the Democratic Republic of the Congo and Uganda: a multicentre, prospective, diagnostic accuracy study 刚果民主共和国和乌干达猴痘快速抗原检测的现场评估：一项多中心、前瞻性、诊断准确性研究 Barnabas Bakamutumaho,David Lupande Mwenebitu,Winters Muttamba,Ingrid Ampeire,Henry Kyobe Bosa,Esto Bahizire,Bertin Casinga Bisimwa,Andrew Obuku,Misaki Wayengera,Alison Sandeman,Matthew T G Holden,Patrick D M C Katoto,Bruce Kirenga,Deborah A Williamson,Wilber Sabiiti The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p260 30 Complications and mortality of typhoid fever: an updated global systematic review and meta-analysis 伤寒热的并发症与死亡率：一项更新的全球系统综述与荟萃分析 Shruti Murthy,Nienke N Hagedoorn,Suzanne Faigan,Meera D Rathan,Christian S Marchello,John A Crump The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p270 31 Global, regional, and national burden of Chagas disease, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023 1990-2023年全球、区域和国家层面查加斯病负担：2023年全球疾病负担研究的系统分析 GBD 2023 Chagas Disease and RAISE Study Collaborators The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p284 32 Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial 乌干达健康成年人中ChAdOx1裂谷热疫苗的安全性、耐受性和免疫原性：一项单中心、单盲、随机、安慰剂对照、剂量递增的1期试验 Zacchaeus Anywaine,Jennifer Serwanga,Abu-Baker Mustapher Ggayi,Andrew Max Abaasa,Daniel Wright,Ben Gombe,Peter Ejou,Tamara Namata,Antony Kigozi,Naboth Tukamwesiga,Vincent Basajja,Violet Ankunda,Dora Jocelyn Mulondo,Florence Nambaziira,Ayoub Kakande,Wilson Kakeeto,Phiona Nabaggala,Daniel Jenkin,Alison Lawrie,Pedro Folegatti,Nguyen Tran,Christian Hansen,Alison M Elliott,Adrian V S Hill,George M Warimwe,Pontiano Kaleebu The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p302 33 Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in children, adolescents, and adults in the USA: a randomised, observer-blind, placebo-controlled, phase 2 trial 美国儿童、青少年和成人基础免疫后18个月VLA15莱姆病疫苗候选物的加强免疫接种的免疫原性和安全性：一项随机、观察者盲法、安慰剂对照的2期试验 Laura Wagner,Michaela Obersriebnig,Romana Hochreiter,Vera Kadlecek,Julian Larcher-Senn,Lisa Hegele,Jason D Maguire,Timothy Murphy,Ulla Derhaschnig,Nicole Bézay,Juan Carlos Jaramillo,Susanne Eder-Lingelbach,Marc Messier The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：p314 SERIES（研讨会） Artificial Intelligence and Infectious Diseases 人工智能与传染病 34 Artificial intelligence and infectious diseases: an evidence-driven conceptual framework for research, public health, and clinical practice 人工智能与传染病：基于证据的研究、公共卫生和临床实践概念框架 Anna Odone,Chiara Barbati,Silvia Amadasi,Tanja Schultz,David B Resnik The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e152 35 Artificial intelligence and infectious disease diagnostics: state of the art and future perspectives 人工智能与传染病诊断：现状与未来展望 Luca Miglietta,Timothy M Rawson,Ronald Galiwango,Alex Tasker,Damien K Ming,Darlington Akogo,Cecilia Ferreyra,Eric O Aboagye,N Claire Gordon,Carolina Garcia-Vidal,Jesus Rodriguez-Manzano,Alison H Holmes The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e168 36 Artificial intelligence and infectious diseases: tackling antimicrobial resistance, from personalised care to antibiotic discovery 人工智能与传染病：应对抗菌药物耐药性，从个性化治疗到抗生素发现 Alex Howard,Nada Reza,Peter L Green,Mo Yin,Erin Duffy,Henry C Mwandumba,Alessandro Gerada,William Hope The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e181 REVIEW（综述） 37 Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia 血液系统恶性肿瘤患者或接受造血细胞移植患者社区获得性呼吸道病毒感染：第10届欧洲白血病感染会议更新建议 Marie von Lilienfeld-Toal,Fareed Khawaja,Francesca Compagno,Christine Robin,José-Luis Piñana,Simone Cesaro,Hermann Einsele,Per Ljungman,David Navarro,Michael Boeckh,Roy F Chemaly,Hans H Hirsch The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e193 CLINICAL PICTURE（临床图像） 38 Mycoplasma hominis toe osteomyelitis: a rare and unusual bone infection 人型支原体足趾骨髓炎：一种罕见且不寻常的骨感染 Cheryl Keel,Pauleen McSherry,Rebecca Thombre,Sendurann Nadarajah,Rediat Tewolde,Owen B Spiller,Baharak Afshar The Lancet Infectious Diseases. Mar 2026，Vol 26(3)：e207

疫苗信使RNA临床1期临床研究

2026-02-25

·PRNewswire

CUMBERLAND PHARMACEUTICALS LAUNCHES U.S. PROMOTION OF TALICIA®

NASHVILLE, Tenn., Feb. 25, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, today announced the launch of its national sales promotional for Talicia ®. Cumberland has assumed responsibility for the distribution and sales promotion of the brand in the U.S. under the co-commercialization agreement with RedHill Biopharma. Talicia is an FDA-approved oral capsule indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer. Talicia is the only all-in-one treatment containing omeprazole, amoxicillin and rifabutin and is now listed as a first-line option in the American College of Gastroenterology guidelines for H. pylori infections. Talicia is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product designation. "We believe this represents an important catalyst for the next phase of Talicia's growth," said A.J. Kazimi, CEO of Cumberland Pharmaceuticals. "We are executing the full breadth of sales and marketing initiatives underway to support Talicia's continued momentum. Our focus is on strengthening prescription growth while expanding number of patients helped by this treatment." The launch expands Cumberland's specialty product portfolio and reflects the company's strategy of leveraging its established commercial infrastructure to drive growth from its differentiated, FDA-approved brands. As part of the launch, Cumberland is utilizing its existing field sales force division with supporting marketing initiatives designed to increase awareness among gastroenterologists and other prescribing physicians. H. pylori infection affects approximately 35% of the U.S. adult population and is a leading cause of gastric cancer, contributing to an estimated 11,000 related deaths annually in the U.S. Cumberland and its commercialization partner are aligning key commercial resources to ensure broader access to this clinically differentiated therapy. About H. pylori H. pylori is a bacterial infection that affects approximately 35% of the U.S. adult population (an estimated 1.6 million U.S. patients are treated annually) rising to more than 50% globally. Classified by the World Health Organization (WHO) as a Group 1 carcinogen, H. pylori is the strongest known risk factor for gastric cancer (between 70% to 90% of cases with more than 27,000 Americans diagnosed with gastric cancer annually and approximately 800,000 deaths globally per year), a major risk factor for peptic ulcer disease (90% of cases) and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain H. pylori-positive due to high resistance of H. pylori to antibiotics, especially clarithromycin, which is still commonly used in standard combination therapies. About Talicia® Approved by the FDA for the treatment of H. pylori infection in adults in November 2019, Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole). Talicia received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents extending patent protection through 2042 with additional patents and applications pending and granted in various territories worldwide. Talicia is also approved by the United Arab Emirates (UAE) Ministry of Health. For full prescribing information, visit . About Cumberland Pharmaceuticals Cumberland Pharmaceuticals Inc. is the largest biopharmaceutical company founded and headquartered in Tennessee and is focused on providing unique products that improve the quality of patient care. The company develops, acquires, and commercializes products for the hospital acute care, gastroenterology and oncology market segments. The company's portfolio of FDA-approved brands includes: Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of pain and fever; Kristalose® (lactulose) oral, a prescription laxative, for the treatment of constipation; Sancuso® (granisetron) transdermal, for the prevention of nausea and vomiting in patients receiving certain types of chemotherapy treatment; Vaprisol® (conivaptan) injection, to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ® (telavancin) injection, for the treatment of certain serious bacterial infections including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Talicia® (omeprazole, amoxicillin and rifabutin) oral capsule, for the treatment of H. pylori infection. The company also has a series of Phase 2 clinical programs underway evaluating its ifetroban product candidate in patients with Systemic Sclerosis and Idiopathic Pulmonary Fibrosis, in addition to Duchenne muscular dystrophy. For more information on Cumberland's approved products, including full prescribing information, please visit the individual product websites, which can be found on the company's website at . Forward-Looking Statements This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. Forward-looking statements include, among other things, statements regarding the company's intent, belief or expectations, and can be identified by the use of terminology such as "may," "will," "expect," "believe," "intend," "plan," "estimate," "should," "seek," "anticipate," "look forward" and other comparable terms or the negative thereof. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's operation results. These factors include macroeconomic conditions, including rising interest rates and inflation, competition, an inability of manufacturers to produce Cumberland's products on a timely basis, failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, natural disasters, public health epidemics, maintaining an effective sales and marketing infrastructure, and other events beyond the company's control as more fully discussed in its most recent annual report on Form 10-K as filed with the U.S. Securities and Exchange Commission ("SEC"), as well as the company's other filings with the SEC from time to time. There can be no assurance that results anticipated by the company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof. SOURCE Cumberland Pharmaceuticals Inc. 21% more press release views with Request a Demo

上市批准临床2期引进/卖出合格传染病产品

2026-02-25

·PRNewswire

Joint U.S. Commercialization of RedHill's Talicia® Commences

The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled out to support accelerated market penetration and expanded reach Focused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1, THI and Cumberland will manage the launch and ongoing joint commercialization activities H. pylori infection affects 35% of the U.S. adult population and an estimated 1.6 million U.S. patients are treated annually2. Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based H. pylori therapy addressing antibiotic resistance and is recommended as an empiric first-line H. pylori therapy in the American College of Gastroenterology (ACG) Clinical Guideline3 RALEIGH, N.C. and TEL-AVIV, Israel, Feb. 25, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that the full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. ("THI") and Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), has started and is now being rolled out to support accelerated market penetration and expanded reach. This marks the operational launch of the joint commercialization model previously announced in October 2025, including Cumberland's $4 million strategic investment. Focused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy, THI, a RedHill and Cumberland jointly controlled operating entity (70/30 RedHill/ Cumberland ownership) will manage the launch and ongoing joint commercialization, in coordination with Cumberland. "H. pylori infection affects 35% of the U.S. adult population and is a leading cause of gastric cancer, responsible for approximately 11,000 related U.S. deaths a year," said Rick Scruggs, President of THI and RedHill's Chief Commercial Officer. "Patients should have access to the most effective, clinically differentiated, therapies designed to eradicate H. pylori infection on the first attempt, while mitigating the risk of antibiotic resistance. We are excited to propel Talicia into its next phase of growth in this expanding market. We are integrating key commercial resources and leveraging our combined expertise to balance stronger prescription growth with the delivery of operational efficiencies as we drive to ensure that more patients benefit from this important therapy." Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based H. pylori therapy designed to address growing antibiotic resistance concerns to other available therapies. It is listed as a first-line H. pylori treatment option in the 2024 American College of Gastroenterology (ACG) Clinical Guideline, which emphasizes using 14-day, "optimized" regimens for the first attempt to maximize cure rates and avoid the need for complex, less-effective salvage therapies4. It is patent protected through 2042 and received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation. Talicia is also the only FDA-approved medication for H. pylori infection with an all-in-one formulation, with the added benefit of simple dosing. RedHill continues to work towards expanding patient access to Talicia globally. Efforts focused on potential new market entries in the UK and the Middle East, along with work to further broaden market access and secure additional non-dilutive ex-U.S. licensing revenue streams, are ongoing. About H. pylori H. pylori is a bacterial infection that affects approximately 35% of the U.S. adult population (an estimated 1.6 million U.S. patients are treated annually) rising to more than 50% globally[4]. Classified by the World Health Organization (WHO) as a Group 1 carcinogen, H. pylori is the strongest known risk factor for gastric cancer (between 70% to 90% of cases with more than 27,000 Americans diagnosed with gastric cancer annually5 and approximately 800,000 deaths globally per year), a major risk factor for peptic ulcer disease (90% of cases)6 and gastric mucosa-associated lymphoid tissue (MALT) lymphoma7. Eradication of H. pylori is becoming increasingly difficult, with current therapies failing in approximately 25-40% of patients who remain H. pylori-positive due to high resistance of H. pylori to antibiotics, especially clarithromycin, which is still commonly used in standard combination therapies8. About Talicia® Approved by the FDA for the treatment of H. pylori infection in adults in November 2019, Talicia is a novel, fixed-dose, all-in-one oral capsule combination of two antibiotics (amoxicillin and rifabutin) and a proton pump inhibitor (omeprazole). Talicia received eight years of U.S. market exclusivity under its Qualified Infectious Disease Product (QIDP) designation and is also covered by U.S. patents extending patent protection through 2042 with additional patents and applications pending and granted in various territories worldwide. Talicia is also approved by the United Arab Emirates (UAE) Ministry of Health. About RedHill Biopharma RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on U.S. development and commercialization of drugs for gastrointestinal diseases, infectious diseases and oncology. RedHill promotes the FDA-approved gastrointestinal drug Talicia®, for the treatment of Helicobacter pylori (H. pylori) infection in adults9, with a recent co-commercialization agreement in the U.S. with Cumberland Pharmaceuticals. RedHill's key clinical late-stage development programs include: (i) opaganib (ABC294640), a first-in-class, orally administered sphingosine kinase-2 (SPHK2) selective inhibitor with anti-inflammatory, antiviral, and anticancer activity, targeting multiple indications with U.S. government and academic collaborations for development for medical countermeasures including radiation and chemical exposure indications such as GI-Acute Radiation Syndrome (GI-ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 study in prostate cancer in combination with darolutamide; (ii) RHB-204, a next-generation optimized formulation of RHB-104, with a planned Phase 2 study for Crohn's disease (based on RHB-104's positive Phase 3 Crohn's disease study results); (iii) RHB-102, with a planned Phase 2 proof-of-concept study for GLP-1/GIP receptor agonist-associated GI intolerance, positive results from a U.S. Phase 3 study for acute gastroenteritis and gastritis, positive results from a U.S. Phase 2 study for IBS-D and potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting. RHB-102 is partnered with Hyloris Pharma (EBR: HYL) for worldwide development and commercialization outside North America; and (iv) RHB-107 ( upamostat), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness, including COVID-19 and also targeting multiple cancer and inflammatory gastrointestinal diseases. More information about the Company is available at / X.com/RedHillBio. TALICIA: INDICATION AND IMPORTANT SAFETY INFORMATION Talicia is a three-drug combination of omeprazole, a proton pump inhibitor, amoxicillin, a penicillin-class antibacterial, and rifabutin, a rifamycin antibacterial, indicated for the treatment of Helicobacter pylori infection in adults. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Talicia and other antibacterial drugs, Talicia should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. Talicia contains omeprazole, a proton pump inhibitor (PPI), amoxicillin, a penicillin-class antibacterial and rifabutin, a rifamycin antibacterial. It is contraindicated in patients with known hypersensitivity to any of these medications, any other components of the formulation, any other beta-lactams or any other rifamycin. Talicia is contraindicated in patients receiving rilpivirine-containing products. Talicia is contraindicated in patients receiving delavirdine or voriconazole. Serious and occasionally fatal hypersensitivity reactions have been reported with omeprazole, amoxicillin and rifabutin. Drug-induced enterocolitis syndrome (DIES) has been reported with use of amoxicillin, a component of Talicia. Severe cutaneous adverse reactions (SCAR) (e.g., Stevens-Johnson syndrome (SJS), Toxic epidermal necrolysis (TEN)) have been reported with rifabutin, amoxicillin, and omeprazole. Additionally, drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported with rifabutin. Acute Tubulointerstitial Nephritis has been observed in patients taking PPIs and penicillins. Clostridioides difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents and may range from mild diarrhea to fatal colitis. Talicia may cause fetal harm. Talicia is not recommended for use in pregnancy. Talicia may reduce the efficacy of hormonal contraceptives. An additional non-hormonal method of contraception is recommended when taking Talicia. Talicia should not be used in patients with hepatic impairment or severe renal impairment. Cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE) have been reported in patients taking PPIs. These events have occurred as both new onset and exacerbation of existing autoimmune disease. The most common adverse reactions (≥1%) were diarrhea, headache, nausea, abdominal pain, chromaturia, rash, dyspepsia, oropharyngeal pain, vomiting, and vulvovaginal candidiasis. To report SUSPECTED ADVERSE REACTIONS, contact RedHill Biopharma INC. at 1-833-ADRHILL (1-833-237-4455) or FDA at 1-800-FDA-1088 or . Full prescribing information for Talicia is available at . Forward Looking Statements This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words, and include, among others, statements regarding the potential impact of the relationship with Cumberland on the commercialization of Talicia. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: the risk that co-commercialization of Talicia with Cumberland may not provide the anticipated commercial and operational benefits to RedHill's global Talicia business or to RedHill's financial position, costs or its broader strategic objectives, including accelerating prescriptions, improving operational efficiencies and enabling more patients to benefit from Talicia; the risk regarding the Company's ability to maintain compliance with Nasdaq's listing requirements, including the minimum stockholders' equity requirement; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk of current uncertainty regarding U.S. government research and development funding and that the U.S. government is under no obligation to continue to support development of our products and can cease such support at any time; the risk that acceptance onto the RNCP Product Development Pipeline or other governmental and non-governmental development programs will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company's proposed development plans for its programs; the risk that the Company's development programs and studies may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional studies may be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company's research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company's ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of any necessary commercial companion diagnostics; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company's receipt of regulatory approvals for its therapeutic candidates, and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company's therapeutic candidates and Talicia®; (v) the Company's ability to successfully commercialize and promote Talicia®; (vi) the Company's ability to establish and maintain corporate collaborations; (vii) the Company's ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company's therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company's business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company's expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company's Expanded Access Program; (xiv) competition from other companies and technologies within the Company's industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 20-F filed with the SEC on April 10, 2025. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law. Category: Corporate [1] IQVIA XPO Data on file [2] Hooi JKY et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153:420-429. [3] Chey W, Howden C, Moss S, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori infection. Am J Gastroenterol. 2024;119:1730-53. [4] Hooi JKY et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017; 153:420-429. [5] National Cancer Institute, Surveillance, Epidemiology, and End Results Program (SEER). [6] Malfertheiner, P., Camargo, M.C., El-Omar, E. et al. Helicobacter pylori infection. Nat Rev Dis Primers 9, 19 (2023). [7] Hu Q et al. Gastric mucosa-associated lymphoid tissue lymphoma and Helicobacter pylori infection: a review of current diagnosis and management. Biomarker research 2016;4.1:15. [8] Malfertheiner P. et al. Management of Helicobacter pylori infection - the Maastricht IV/ Florence Consensus Report, Gut 2012;61:646-664; O'Connor A. et al. Treatment of Helicobacter pylori Infection 2015, Helicobacter 20 (S1) 54-61; Venerito M. et al. Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection. Digestion 2013;88(1):33-45. [9] Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: . Logo - SOURCE RedHill Biopharma Ltd. 21% more press release views with Request a Demo

临床结果临床2期临床3期引进/卖出上市批准

100 项与克拉霉素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00276	克拉霉素	J01FA09	DB01211

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
细胞内鸟分枝杆菌感染	日本	Mylan Pharmaceuticals, Inc.	2009-10-06
猩红热	日本	Mylan Pharmaceuticals, Inc.	2006-03-15
继发感染	日本	Mylan Pharmaceuticals, Inc.	2006-03-15
社区获得性肺炎	美国	AbbVie, Inc.	2000-03-03
下呼吸道感染	中国	丽珠集团丽珠制药厂	1996-01-01
下呼吸道感染	中国	西安利君制药有限责任公司	1996-01-01
急性上颌窦炎	美国	AbbVie, Inc.	1991-10-31
急性中耳炎	美国	AbbVie, Inc.	1991-10-31
慢性支气管炎	美国	AbbVie, Inc.	1991-10-31
十二指肠溃疡	美国	AbbVie, Inc.	1991-10-31
幽门螺杆菌感染	美国	AbbVie, Inc.	1991-10-31
HIV感染	美国	AbbVie, Inc.	1991-10-31
感染	美国	AbbVie, Inc.	1991-10-31
分枝杆菌感染	美国	AbbVie, Inc.	1991-10-31
非结核分枝杆菌感染	美国	AbbVie, Inc.	1991-10-31
风湿热	美国	AbbVie, Inc.	1991-10-31
脓肿	日本	Taisho Pharmaceutical Co., Ltd.	1991-03-29
急性支气管炎	日本	Taisho Pharmaceutical Co., Ltd.	1991-03-29
细菌感染	日本	Taisho Pharmaceutical Co., Ltd.	1991-03-29
支气管炎	日本	Nippon Chemiphar Co., Ltd.	1991-03-29

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
急性细菌性鼻窦炎	临床3期	美国	Abbott Laboratories	2003-05-01
急性细菌性鼻窦炎	临床3期	加拿大	Abbott Laboratories	2003-05-01
急性细菌性鼻窦炎	临床3期	希腊	Abbott Laboratories	2003-05-01
急性细菌性鼻窦炎	临床3期	匈牙利	Abbott Laboratories	2003-05-01
急性细菌性鼻窦炎	临床3期	意大利	Abbott Laboratories	2003-05-01
急性细菌性鼻窦炎	临床3期	立陶宛	Abbott Laboratories	2003-05-01
急性细菌性鼻窦炎	临床3期	波兰	Abbott Laboratories	2003-05-01
急性细菌性鼻窦炎	临床3期	罗马尼亚	Abbott Laboratories	2003-05-01
急性细菌性鼻窦炎	临床3期	西班牙	Abbott Laboratories	2003-05-01
克罗恩病	临床3期	英国	Abbott Laboratories	2000-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02542657 (Pubmed \| Blood Neoplasia)	临床1/2期	难治性多发性骨髓瘤	28	Clarithromycin+Ixazomib+Pomalidomide+Dexamethasone	選鑰蓋餘選簾範窪淵簾(顧壓憲構願積鹹窪選醖) = 衊範構選窪齋遞壓艱構齋餘築齋製齋衊積獵艱 (觸繭遞淵築遞淵糧淵齋 ) 更多	积极	2025-08-01
NCT04724044 (ACCESS, Pubmed) 人工标引	临床3期	社区获得性肺炎 procalcitonin	267	Standard of care + Clarithromycin	衊構艱壓獵膚顧艱鬱衊(積鏇蓋憲襯構範窪範顧) = 齋廠鹹齋餘餘鏇鬱獵鹹鹹夢蓋糧鹽鹹繭構鏇憲 (願壓衊膚衊醖顧齋鏇鹹 ) 更多	积极	2024-01-01
				Standard of care + placebo	衊構艱壓獵膚顧艱鬱衊(積鏇蓋憲襯構範窪範顧) = 蓋製製醖鏇繭遞鬱壓積鹹夢蓋糧鹽鹹繭構鏇憲 (願壓衊膚衊醖顧齋鏇鹹 ) 更多
NCT02516696 (BiRd vs Rd, CTgov)	临床3期	多发性骨髓瘤	12	Lenalidomide+Clarithromycin+Dexamethasone (BiRD Treatment Regimen)	齋簾範艱窪積築蓋憲遞(網鬱獵壓構夢積鹹範鬱) = 遞蓋範糧廠鬱鑰鹽夢築夢醖構簾蓋積選簾夢艱 (願選鹹夢窪齋窪餘廠遞, 餘廠鑰鑰衊鹹簾積齋鏇 ~ 襯鹹簾遞積齋壓範獵範) 更多	-	2023-06-05
				Lenalidomide+Dexamethasone (Rd Treatment Regimen)	齋簾範艱窪積築蓋憲遞(網鬱獵壓構夢積鹹範鬱) = 鏇築觸積鑰衊糧憲網築夢醖構簾蓋積選簾夢艱 (願選鹹夢窪齋窪餘廠遞, 網積憲構醖醖膚鏇簾廠 ~ 壓壓糧鹽蓋繭淵壓廠艱) 更多
NCT02019875 (CTgov)	早期临床1期	-	92	Placebo (Water)	製鏇鹽壓選廠憲淵築鬱(壓簾壓獵構願觸艱艱鹽) = 鏇積窪壓鏇淵窪壓襯夢憲網範齋範廠艱繭積憲 (繭膚艱築齋鬱蓋醖衊築, 壓鑰壓壓築蓋鹹網積築 ~ 範遞鹽齋願艱壓襯艱夢) 更多	-	2023-04-19
				Rifampin (Rifampin)	製鏇鹽壓選廠憲淵築鬱(壓簾壓獵構願觸艱艱鹽) = 積鏇憲構顧繭鑰積齋艱憲網範齋範廠艱繭積憲 (繭膚艱築齋鬱蓋醖衊築, 衊鹹選鑰願糧夢鬱廠糧 ~ 壓鑰鑰淵選鬱膚網淵夢) 更多
NCT05342532 (CTgov)	临床4期	幽门螺杆菌感染	112	Omeprazole+Amoxicillin (High Dose Dual Therapy)	憲淵簾顧範顧齋醖範積 = 願淵繭範襯繭觸範膚醖廠廠衊製壓鏇製衊構願 (襯觸淵鑰廠觸窪鹽膚鹹, 廠遞蓋遞範鹹鏇糧簾壓 ~ 鑰憲鑰繭鏇壓蓋糧壓艱) 更多	-	2023-02-01
				Omeprazole+Amoxicillin+Clarithromycin (Standard Triple Therapy)	憲淵簾顧範顧齋醖範積 = 餘餘網選鑰鹹願鏇壓製廠廠衊製壓鏇製衊構願 (襯觸淵鑰廠觸窪鹽膚鹹, 襯遞願蓋顧製顧艱築窪 ~ 構觸鹽憲鬱糧蓋網窪廠) 更多
NCT03440112 (GABA-A, CTgov)	临床1/2期	共济失调 \| 帕金森病	34	Flumazenil (Transdermal Flumazenil (Active))	膚繭憲獵蓋築膚範窪簾(窪鏇夢壓鬱醖壓窪鏇獵) = 餘觸鑰廠構鏇簾壓窪醖獵襯鏇壓鑰築遞簾繭廠 (糧糧遞膚糧顧餘鹹夢簾, 醖齋廠選簾顧淵選襯顧 ~ 艱餘齋衊構範膚鹽淵艱) 更多	-	2023-01-10
				Placebo (Placebo Cream)	膚繭憲獵蓋築膚範窪簾(窪鏇夢壓鬱醖壓窪鏇獵) = 構窪網範範醖淵鹹築壓獵襯鏇壓鑰築遞簾繭廠 (糧糧遞膚糧顧餘鹹夢簾, 衊構範積蓋鹽蓋鹽遞願 ~ 鹹鑰構衊餘鏇鑰鬱簾鹹) 更多
EUCTR2017-001056-55-BE \| NCT03345992 (Pubmed \| Crit Care)	临床3期	多器官功能衰竭 \| 脓毒症	110	Clarithromycin	餘憲艱膚憲獵網艱餘繭(鬱鹹簾壓願憲製顧淵餘) = 製觸醖蓋艱願願積簾壓鹽齋製夢範廠網網構繭 (膚構糧範繭觸鏇鏇餘獵 )	不佳	2022-06-18
				Placebo	餘憲艱膚憲獵網艱餘繭(鬱鹹簾壓願憲製顧淵餘) = 網鹽網獵築製醖製醖構鹽齋製夢範廠網網構繭 (膚構糧範繭觸鏇鏇餘獵 )
IMS2021	临床1/2期	难治性多发性骨髓瘤	32	Pomalidomide	窪顧壓繭積襯蓋鏇獵夢(衊遞簾築齋獵築構鬱齋) = 繭襯艱鹽鏇築夢遞網壓願糧淵窪醖齋鑰鏇獵鹽 (醖鏇鹹蓋觸齋餘夢簾範 ) 更多	-	2021-09-08
NCT04398004 (ACHIEVE, Pubmed \| Infect Dis Ther)	临床2期	新型冠状病毒感染	90	Oral Clarithromycin	構壓夢繭鑰夢窪鏇醖獵(餘蓋築遞遞淵糧構夢構) = 鏇鹽醖鏇製襯範鏇醖餘鹽簾憲觸獵範壓餘淵顧 (簾鏇鹽蓋鬱構蓋觸鹹艱, 78.1 ~ 92.2)	积极	2021-08-06
NCT02575144 (GEM-CLARIDEX, Pubmed \| Blood Cancer J) 人工标引	临床3期	多发性骨髓瘤	286	Lenalidomide+dexamethasone+clarithromycin	築夢築淵齋鏇網糧顧窪(獵簾壓網選網範遞築網) = 鬱鑰廠製遞淵築憲窪淵鹹廠顧壓簾鹹淵願範網 (選夢夢願築簾夢蓋淵獵 ) 更多	不佳	2021-05-21
				Lenalidomide+dexamethasone	築夢築淵齋鏇網糧顧窪(獵簾壓網選網範遞築網) = 顧選齋憲構獵艱蓋選衊鹹廠顧壓簾鹹淵願範網 (選夢夢願築簾夢蓋淵獵 ) 更多